The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia
Abstract
References
- Laurenti L, Tarnani M, De Padua L, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in pa- tients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hema- tol 2008;87:891-8.
- Catovsky D, Richards S, Matutes E, et al. Assessment of flu- darabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:197-8.
- Lin TS. What is the optimal initial treatment for chron- ic lymphocytic leukemia? Oncology (Williston Park) 2007;21:1641-9
- Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunother- apy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:479- 80.
- Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral flu- darabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008;26:247-51.
- Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral flu- darabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90-3.
- Cazin B, Divine M, Leprêtre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclo- phosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008;143:54-9. 2008;143:54-9.
The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia
Abstract
The aim of this study was to evaluate the efficiency, as well as the hematologic and non-he
Keywords
References
- Laurenti L, Tarnani M, De Padua L, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in pa- tients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hema- tol 2008;87:891-8.
- Catovsky D, Richards S, Matutes E, et al. Assessment of flu- darabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:197-8.
- Lin TS. What is the optimal initial treatment for chron- ic lymphocytic leukemia? Oncology (Williston Park) 2007;21:1641-9
- Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunother- apy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:479- 80.
- Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral flu- darabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008;26:247-51.
- Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral flu- darabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90-3.
- Cazin B, Divine M, Leprêtre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclo- phosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008;143:54-9. 2008;143:54-9.
There are 7 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Letter to the Editor |
| Authors | |
| Publication Date | March 1, 2010 |
| Published in Issue | Year 2010 |